Table 3.
Number and Percentage of Moderate-to-Severe Influenza-like Illness (ILI) Episodes Positive for Respiratory Syncytial Virus (RSV: Any and by Subtype) or Any Virus by Country
| Country | Total Samples |
RSV Episodes |
RSV Subtype A |
RSV Subtype B |
Any Virus Detected |
|||||
|---|---|---|---|---|---|---|---|---|---|---|
| nb | % of Total | n | % (95% CI) | n | % (95% CI) | n | % (95% CI) | n | % (95% CI) | |
| Belgium | 20 | 3.6 | 1 | 5.0 (.1–24.9) | 1 | 5.0 (.1–24.9) | 0 | 0.0 (.0–16.8) | 14 | 70.0 (45.7–88.1) |
| Canada | 38 | 6.8 | 2 | 5.3 (.6–17.7) | 0 | 0.0 (.0–9.3) | 2 | 5.3 (.6–17.7) | 18 | 47.4 (31.0–64.2) |
| Czech Rep. | 70 | 12.6 | 12 | 17.1 (9.2–28.0) | 2 | 2.9 (.3–9.9) | 10 | 14.3 (7.1–24.7) | 53 | 75.7 (64.0–85.2) |
| Estonia | 17 | 3.1 | 0 | 0.0 (.0–19.5) | 0 | 0.0 (.0–19.5) | 0 | 0.0 (.0–19.5) | 8 | 47.1 (23.0–72.2) |
| France | 30 | 5.4 | 1 | 3.3 (.1–17.2) | 1 | 3.3 (.1–17.2) | 0 | 0.0 (.0–11.6) | 17 | 56.7 (37.4–74.5) |
| Germany | 47 | 8.5 | 7 | 14.9 (6.2–28.3) | 3 | 6.4 (1.3–17.5) | 4 | 8.5 (2.4–20.4) | 26 | 55.3 (40.1–69.8) |
| Mexico | 50 | 9.0 | 1 | 2.0 (.1–10.6) | 0 | 0.0 (.0–7.1) | 1 | 2.0 (.1–10.6) | 31 | 62.0 (47.2–75.3) |
| Netherlands | 45 | 8.1 | 3 | 6.7 (1.4–18.3) | 2 | 4.4 (.5–15.1) | 1 | 2.2 (.1–11.8) | 33 | 73.3 (58.1–85.4) |
| Norway | 13 | 2.3 | 2 | 15.4 (1.9–45.4) | 1 | 7.7 (.2–36.0) | 1 | 7.7 (.2–36.0) | 8 | 61.5 (31.6–86.1) |
| Poland | 90 | 16.2 | 10 | 11.1 (5.5–19.5) | 3 | 3.3 (.7–9.4) | 7 | 7.8 (3.2–15.4) | 59 | 65.6 (54.8–75.3) |
| Romaniaa | 21 | 3.8 | 2 | 9.5 (1.2–30.4) | 1 | 4.8 (.1–23.8) | 1 | 4.8 (.1–23.8) | 10 | 47.6 (25.7–70.2) |
| Russian Fed. | 98 | 17.6 | 0 | 0.0 (.0–3.7) | 0 | 0.0 (.0–3.7) | 0 | 0.0 (.0–3.7) | 36 | 36.7 (27.2–47.1) |
| Taiwan | 4 | 0.7 | 0 | 0.0 (.0–60.2) | 0 | 0.0 (.0–60.2) | 0 | 0.0 (.0–60.2) | 1 | 25.0 (.6–80.6) |
| UK – CMD | 13 | 2.3 | 0 | 0.0 (.0–24.7) | 0 | 0.0 (.0–24.7) | 0 | 0.0 (.0–24.7) | 6 | 46.2 (19.2–74.9) |
| Total | 556 | 100 | 41 | 7.4 (5.3–9.9) | 14 | 2.5 (14–4.2) | 27 | 4.9 (3.2–7.0) | 320 | 57.6 (53.3–61.7) |
Abbreviations: CI, confidence interval; UK, United Kingdom.
a Concerns about data integrity from a single study site in Romania that enrolled 102 subjects arose after completion of the analysis. Because evaluation of data from this site showed no irregularities when compared with the total cohort, and because GlaxoSmithKline Vaccines has no current plans to use the study data to support any regulatory activity, data from this site were included in the present analysis.
b n, no. of subjects in a given category.